GLAXO WELLCOME ULTIVA ANALGESIC OPIOID RAPID ONSET/OFFSET TIME IN GENERAL ANESTHESIA ACHIEVES EFFECT WITHOUT DELAYING PATIENT RECOVERY -- FDA CMTE.
Executive Summary
Glaxo Wellcome's Ultiva (remifentanil) is different from other opioid analgesics because its half-life of three to six minutes allows for a much more rapid onset/offset time, the company said during an April 29 presentation before FDA's Anesthetic & Life Support Advisory Committee, which recommended Ultiva for approval. Glaxo's NDA submission was filed in September 1995.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: